Xcout IntelSign inSubscribe

Tiger Biotherapeutics Inc.

Biotechnology & Medical TechnologyCranbury, NJ, United States

Tiger Biotherapeutics Inc. is a regenerative medicine company that develops and provides advanced cellular, acellular, and matrix-like products (CAMPs) for wound care, aesthetics, and tissue science. The company serves healthcare providers and patients by offering solutions for tissue repair, wound closure, and reconstructive or cosmetic applications.

Subscribe to see Tiger Biotherapeutics Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event

Tiger Biotherapeutics Inc. at a glance

Tiger Biotherapeutics Inc. is a biotechnology & medical technology company headquartered in Cranbury, United States. Its most recent funding round raised $20M in March 2023. Xcout tracks 8 named people at Tiger Biotherapeutics Inc., including Caroline Van Hove (President, Tiger Aesthetics Medical).

As of 16 November 2026. Source: Xcout Intel.

Industry
Biotechnology & Medical Technology
Headquarters
Cranbury, NJ, United States

Tiger Biotherapeutics Inc. leadership

  • Caroline Van HovePresident, Tiger Aesthetics Medical
  • Garrett GrinsfelderPresident, Tiger Wound Care
  • Monica GarciaChief Operating Officer
  • David FischerChief Financial Officer
  • John Jay WebsterChief People Officer
  • Larry Buzz Wood, Jr.Chief Legal Officer

2 more named people on record for Tiger Biotherapeutics Inc., with roles, board committees and tenure — see the full roster →

Tiger Biotherapeutics Inc. funding rounds

Every round on record:

DateRoundAmountInvestors
SEC Form D filing$20M—

Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →

Tiger Biotherapeutics Inc. competitors

A few of Tiger Biotherapeutics Inc.'s closest competitors — see the full list of competitors and alternatives →

Organogenesis Holdings Inc.ORGO · BiotechCanton, MA, United States
68% matchPublic

Organogenesis Holdings Inc. is a U.S.-based regenerative medicine firm that specializes in creating, producing, and marketing innovative therapies for advanced wound management, as well as surgical and sports medicine applications. Within its advanced wound care portfolio, Organogenesis offers several distinct products. These include Affinity and Novachor, both amniotic membrane dressings designed to preserve vital cells, growth factors, and ECM proteins found in natural tissue. Apligraf is a bioengineered living cell therapy that releases a range of healing cytokines and growth factors, while Dermagraft is another bioengineered solution that generates human collagen, ECM, proteins, and cytokines. NuShield provides a wound covering incorporating both amnion and chorion membranes to maintain a spongy intermediate layer. PuraPly acts as an antimicrobial barrier, allowing for flexibility and effective fluid drainage. For the surgical and sports medicine sectors, the company provides products such as NuCel, a dehydrated placental tissue designed for surgical application to promote natural tissue regeneration. ReNu is a cryopreserved suspension aimed at aiding soft tissue recovery. Additionally, FiberOS and OCMP serve as bone void fillers, primarily utilized in orthopedic and neurosurgical procedures. Looking ahead, Organogenesis's product pipeline features PuraPly XT and PuraPly MZ, which are being developed for treating chronic, acute, and open wounds. PuraForce is a bioengineered porcine collagen surgical matrix intended for soft tissue reinforcement. TransCyte, another bioengineered tissue, is in development for addressing partial thickness burns. Organogenesis distributes its offerings to a diverse client base, including hospitals, specialized wound care centers, government institutions, ambulatory surgical centers, and physician offices, leveraging both its direct sales team and independent agencies. Established in 1985, the company maintains its headquarters in Canton, Massachusetts.

Market cap$124.8M
Employees869
Organogenesis Holdings Inc. competitors & alternatives →

Get Tiger Biotherapeutics Inc.'s news by email

Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.

Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →

Something wrong or missing about Tiger Biotherapeutics Inc.? Suggest a correction · Work at Tiger Biotherapeutics Inc.? Claim this profile

Is this your company? Add the Xcout Intel badge to your website

Free, for any company on Xcout Intel. It links visitors to this profile.

Tiger Biotherapeutics Inc. on Xcout Intel

Share this card

Post the link and the card appears automatically — each network fetches the image itself.

Tiger Biotherapeutics Inc. — share card preview

Instagram, TikTok and Slack canvases don't expand links — download the card as a PNG and post it as an image instead.

More on Tiger Biotherapeutics Inc. in Xcout Intel

  • 8 named people with titles, LinkedIn and board committees
  • 1 funding round with the investors in each, and who they co-invest with
  • The full competitor set, tracking, exports and API access
Subscribe to Xcout Intel →